Virios Therapeutics, Inc. (VIRI): Price and Financial Metrics
GET POWR RATINGS... FREE!
VIRI Stock Price Chart Interactive Chart >
VIRI Price/Volume Stats
|Current price||$4.32||52-week high||$7.45|
|Prev. close||$4.19||52-week low||$3.30|
|Day high||$4.47||Avg. volume||20,653|
|50-day MA||$4.35||Dividend yield||N/A|
|200-day MA||$5.16||Market Cap||35.99M|
Virios Therapeutics, Inc. (VIRI) Company Bio
Virios Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response including fibromyalgia. It offers IMC-1 a novel, proprietary, fixed dose combination of famciclovir and celecoxib. The company was founded by William L. Pridgen on February 28, 2012 and is headquartered in Alpharetta, GA.
Most Popular Stories View All
VIRI Latest News Stream
|Loading, please wait...|
VIRI Latest Social Stream
View Full VIRI Social Stream
Latest VIRI News From Around the Web
Below are the latest news stories about Virios Therapeutics Inc that investors may wish to consider to help them evaluate VIRI as an investment opportunity.
NASDAQ:VIRI Richard Hantke: Hello everyone. My name's Richard Hantke. I'm with Zacks Small Cap Research, and welcome to the first in a new series of fireside chats. I am here with Greg Duncan, Chairman and CEO of Virios Therapeutics (NASDQ:VIRI). Hi Greg. Greg Duncan: Very nice to see you Richard. Richard Hantke: Zacks Small Cap Research is a division of Zacks Investment Research, and we focus on
ORLANDO, FL / ACCESSWIRE / January 26, 2022 / RedChip Companies, Inc., an international investor relations, media, and research firm focused on microcap and small-cap companies, is pleased to announce its partnership with Benzinga to host an exclusive series of CEO interviews on January 28, beginning at 9:15 a.
ATLANTA, January 04, 2022--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference, which is taking place virtually January 10 - 13, 2022.
Virios Therapeutics, Inc. (NASDAQ:VIRI) CEO Gregory Scott Duncan acquired 5,000 shares of Virios Therapeutics stock in a transaction dated Tuesday, December 21st. The shares were acquired at an average price of $5.52 per share, with a total value of $27,600.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is 
Virios Therapeutics, Inc. (NASDAQ:VIRI) CEO Gregory Scott Duncan acquired 5,000 shares of Virios Therapeutics stock in a transaction dated Tuesday, December 21st. The shares were acquired at an average price of $5.52 per share, with a total value of $27,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is 
VIRI Price Returns